What is Zacks Research’s Estimate for Omnicell Q1 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Equities researchers at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Omnicell in a report released on Thursday, February 26th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.13 for the quarter, up from their previous estimate of $0.09. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s FY2026 earnings at $0.87 EPS, Q1 2027 earnings at $0.28 EPS, Q4 2027 earnings at $0.29 EPS, FY2027 earnings at $1.11 EPS and FY2028 earnings at $1.40 EPS.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The business had revenue of $313.98 million for the quarter, compared to the consensus estimate of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.Omnicell’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

Several other brokerages have also recently commented on OMCL. Benchmark boosted their price objective on shares of Omnicell from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Wells Fargo & Company increased their price target on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Wall Street Zen cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Wednesday, February 4th. Finally, Weiss Ratings upgraded Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, February 9th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Omnicell Stock Down 2.0%

OMCL opened at $41.10 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14. The company has a market cap of $1.87 billion, a PE ratio of 1,027.76, a price-to-earnings-growth ratio of 1.47 and a beta of 0.79. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.00. The company has a 50 day moving average of $45.05 and a 200 day moving average of $38.01.

Institutional Investors Weigh In On Omnicell

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its position in Omnicell by 9.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock valued at $71,985,000 after purchasing an additional 197,462 shares during the last quarter. Wellington Management Group LLP raised its stake in Omnicell by 156.4% during the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after buying an additional 1,265,818 shares during the last quarter. Lazard Asset Management LLC boosted its stake in Omnicell by 3.8% in the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock worth $50,225,000 after purchasing an additional 62,733 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Omnicell by 2.6% in the second quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock worth $35,163,000 after buying an additional 30,678 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of Omnicell during the third quarter valued at $25,625,000. 97.70% of the stock is currently owned by institutional investors.

Insider Transactions at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the transaction, the executive vice president directly owned 91,674 shares of the company’s stock, valued at $4,574,532.60. The trade was a 6.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.52% of the stock is currently owned by insiders.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.